NCT03715946View on ClinicalTrials.gov

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2024

Conditions
Carcinoma, Squamous Cell of Head and NeckOropharynx Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab Injection

A fully human anti-programmed death 1 (PD-1) monoclonal antibody

RADIATION

Radiotherapy (RT)

45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week

Trial Locations (3)

15232

UPMC Hillman Cancer Center, Pittsburgh

30308

Winship Cancer Institute @ Emory University Hospital Midtown, Atlanta

97213

Providence Cancer Institute, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Robert L. Ferris, MD, PhD

OTHER